Durham, North Carolina-based orthobiologics company Bioventus, Inc. has entered into a definitive agreement to acquire Farmingdale, New York-based Misonix, Inc., in a cash and stock transaction valued at approximately $518 million.
Bioventus to Acquire Misonix for Approx. $500 million
1 min read Premium comments
#bioventusSecondary#misonix
Misonix commercializes a variety of regenerative medicine, minimally invasive technologies and tissue products like SonaStar and BoneScalpel which promote bone sculpting and remove tumors and tissue. The company’s primary products address orthopedic, neurosurgery, and plastic and maxillo-facial surgery needs. In addition, Misonix commercializes Therion, TheraGenesis, and SonicOne which help surgeons debride and promote healing in both acute and chronic trauma wound cases.
Bioventus is a leading orthopedic medical technology company. Bioventus utilizes internal product development, distribution agreements and product and business acquisitions to meet global needs for cost-effective and efficient minimally invasive orthopedic treatments. Established in 2012, the company has over 850 employees worldwide and has additional, international headquarters in Hoofddorp, The Netherlands.
This transaction, which has been unanimously approved by the boards of directors of both Bioventus and Misonix, will create a regenerative medicine and orthopedics medtech company with a wide range of biologic and regenerative products serving a $15 billion market. The combined company will conduct business as Bioventus, Inc.
The agreement transaction is projected to close in the fourth quarter of 2021 and is subject to regulatory approvals as well as Misonix and Bioventus stockholder and customary closing conditions. Misonix stockholders will receive stock or cash value estimates of around $518 million in total, based on weekly volume-weighted average stock prices.
“We are thrilled to announce this agreement to combine with Bioventus and realize our next phase of commercial development,” said Misonix CEO Stavros Vizirgianakis. “Bioventus shares Misonix’s commitment to improving patient outcomes, and we believe this combination will create value for our shareholders as the combined organization continues to drive innovation and increase physician demand.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.